Literature DB >> 19853541

A single LC-tandem mass spectrometry method for the simultaneous determination of four H2 antagonists in human plasma.

Xiuhong Sun1, Yuan Tian, Zunjian Zhang, Yun Chen.   

Abstract

A sensitive and universal LC-MS/MS method for the simultaneous determination of famotidine, cimetidine, ranitidine and lafutidine in human plasma was presented. This is the first single LC-MS/MS method reported for the simultaneous analysis of these four H(2) antagonists in human plasma. Following liquid-liquid extraction with ethyl acetate, the separation was performed on an Agilent Zorbax SB-CN (150 mm x 2.1mm I.D., 5 microm) column using a mobile phase consisted of methanol:20 mM ammonium acetate (55:45, v/v). The total run time was 7 min per sample. Quantification was performed by electrospray ionization-triple quadrupole mass spectrometry by selected reaction monitoring (SRM) detection in the positive mode. All calibration curves showed good linear regression (r(2)>0.99) from 0.5 to 1000 ng/mL for famotidine and lafutidine, and 5-20,000 ng/mL for cimetidine and ranitidine. The method showed good precision and accuracy with overall intra- and inter-day variations of 1.37-9.29% and 3.51-9.40%, respectively. The assay was successfully applied to a bioequivalence study using ranitidine as the model compound.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853541     DOI: 10.1016/j.jchromb.2009.10.003

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry.

Authors:  Xiaoming Wang; Erik Rytting; Doaa R Abdelrahman; Tatiana N Nanovskaya; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biomed Chromatogr       Date:  2013-02-12       Impact factor: 1.902

2.  Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.

Authors:  Marie-Laure Boof; Atef Halabi; Mike Ufer; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2019-12-13       Impact factor: 2.953

3.  Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.

Authors:  Im-Sook Song; Tae Yeon Kong; Hyeon-Uk Jeong; Eun Nam Kim; Soon-Sang Kwon; Hee Eun Kang; Sang-Zin Choi; Miwon Son; Hye Suk Lee
Journal:  BMC Complement Altern Med       Date:  2014-07-17       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.